Mesa Labs in $180m Gyros acquisition for biopharma asset development
Gyros Protein Technologies (GPT) specializes in providing immunoassay and peptide synthesis solutions, which Mesa Laboratories will utilize as the ‘core’ of its new platform, Biopharmaceutical Development.
The acquisition will see Mesa Labs spend $180m (€163m) in cash for the Uppsala, Sweden-based company, which adds to its own capabilities in providing quality control instruments and consumables.
Mesa Labs noted that it expects the deal to add between $37m and $40m in revenue during the first 12 months, as well as projecting growth in double digits over the ‘next several years’.
“The Gyrolab immunoassay solution is a proven, microfluidic driven platform that increases repeatability and throughput while minimizing sample size and manual
handling,” said Gary Owens, CEO of Mesa Labs.
He added, “The company also provides a leading peptide synthesis platform delivering the highest quality peptides in particular, for the longer and more complicated sequences that are of vital interest to many applications, including that of therapeutic peptides and neoantigen therapies.”
According to Mesa, GPT’s product sales are made up of approximately 75% immunoassays and 25% peptide synthesis, with the majority of its customers, around 90%, being based in North America and Europe.
In addition, GPT also supplies reagents, resins, coupling agents, as well as providing qualification work for the installation and operation of synthesis products.
